FDA approve Susvimo for wet age-related macular degeneration
October 29, 2021Medical Communications
Genentech have announced that Susvimo, previously known as the port delivery system, is the fist wet age-related macular degeneration (AMD) …
XBiotech to launch novel therapy for stroke patients in US
October 29, 2021Medical Communications
Clinical stage biopharmaceutical company, XBiotech, plans to test its new True Humanâ„¢ antibody therapy for reducing brain injury after stroke, …
Angel Pharmaceuticals receives IND approval for Phase 1/1b Inhibitor in China
October 28, 2021Business Services
Angel Pharmaceuticals has received approval for their IND application, from the Center for Drug Evaluation (CDE) of the China National …
Serial radiation therapy safe as alternative treatment for kidney cancer
October 28, 2021Business Services
The University of Texas MD Anderson Cancer Center has reported that Serial radiation therapy as monotherapy is a safe and …
First long-acting HIV-treatment to be distributed in European countries
October 28, 2021Business Services
ViiV Healthcare, the global specialist HIV company, have presented positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first …
FDA approves Phase II clinical trial of combination treatment for COVID-19
October 28, 2021Business Services
The FDA has approved Vitti Labs’ Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination …
Plan C COVID strategy being discussed by government
October 27, 2021Research and Development
An advisor to the Department of Health told MPs a ‘Plan C’ has been mentioned in Government discussions, should the …
Quell Therapeutics receives CTA approval to begin first clinical trial with a multi-modular engineered treg cell company
October 27, 2021Research and Development
The MHRA has approved Quell Therapeutics’ first clinical trial for its lead cell therapy candidate QEL-001. This approval paves the …
Study finds link between COVID-19 infection and neurological complications
October 27, 2021Research and Development
A study conducted by Nature Medicine has revealed an increased risk of Guillain-Barre Syndrome (GBS) and Bell’s palsy following a …
FDA and EMA approve Novartis’ treatment for follicular lymphoma patients
October 27, 2021Research and Development
The FDA and EMA have accepted Novartis’ Supplemental Biologics License Application (sBLA) and Type II Variation for KymriahⓇ in patients …
NIHR funds COVID-19 antiviral trial
October 26, 2021Manufacturing and Production
The National Institute for Health research has awarded funding to the University of Oxford, working with several other UK universities, …
CHMP begins rolling review of COVID oral antiviral
October 26, 2021Manufacturing and Production
The EMA’s human medicine’s committee (CHMP) has initiated a rolling review of the investigational antiviral drug molnupiravir for the treatment …
Hospitals and pharmacies facing medicine shortages, says The London Economic
October 26, 2021Manufacturing and Production
As the NHS faces soaring waiting lists and prepares for a winter surge in COVID cases, they must also gear …
MHRA licenses uterine fibroid treatment for women in Great Britain
October 26, 2021Manufacturing and Production
The MHRA has granted a licence for Ryeqo (a relugolix combination therapy), for the treatment of moderate to severe symptoms …
Infectious disease expert says children between 5-11 could be vaccinated in November
October 25, 2021Sales and Marketing
Infectious disease expert, Dr Anthony Fauci, has said that COVID-19 vaccines for children aged 5-11 could be available by early …
More people self-funding routine operations as NHS waiting lists hit record levels
October 25, 2021Sales and Marketing
New data from the Private Healthcare Information Network (PHIN) reveals that people are increasingly opting to self-fund private treatment. This …
Novartis Phase III study into canakinumab does not meet primary endpoint
October 25, 2021Sales and Marketing
Novartis have announced that their CANOPY-1 Phase III study, which evaluated the efficacy of canakinumab, did not meet its primary …
AstraZeneca biliary cancer drug shows improved survival rate in patients
October 25, 2021Sales and Marketing
AstraZeneca has announced that its Imfinzi drug, for the treatment of biliary tract cancer, has improved overall survival in patients …
Companion test for lung cancer approved by FDA
October 22, 2021Medical Communications
The US FDA has approved of the Roche VENTANA PD-L1 Assay as a companion diagnostic for Tecentriq® in non-small cell …
Servier Phase III colorectal cancer trial fails to meet primary endpoint
October 22, 2021Medical Communications
Global independent pharmaceutical group, Servier, has announced that the primary objective (progression free survival) of the Phase III SOLSTICE trial …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
